Advanced Prostate Cancer Patients Finally Have Another Option

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA).

Men's Health Network (MHN) is excited to see this innovative treatment option made available for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. Provenge harnesses the individual's own immune system to fight cancer through a process called active cellular immunotherapy.

Provenge offers hope for men (and their families) to potentially extend and improve the quality of life for those who are suffering from advanced prostate cancer.  Patients should work with their healthcare providers to determine if they are an appropriate candidate for Provenge at this time.

There is an immense need for more options and awareness about the plight of men with advanced prostate cancer. MHN is very excited that the approval of Provenge brings us one step closer to this goal by adding a breakthrough treatment option for these men.  Men now have an opportunity to engage in a conversation with their health care provider about this new innovative immunotherapy to potentially extend and improve their quality of life.

For more information about prostate cancer, please visit www.menshealthnetwork.org or call us at 866-543-6461, extension 101.

About Men's Health Network

Men's Health Network (www.menshealthnetwork.org) is a national non-profit organization whose mission is to reach men and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation.

SOURCE Men's Health Network

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED